Industry News

IIROC Trade Resumption - CTX
Pfizer Inc., the Eastern Connecticut Symphony Orchestra, Eugene O'Neill Theatre Center and the town and cities of Groton and New London. Those were just some of the 40 or so supporters who showed up Wednesday for the first public airing of an initiative intended to attract high-growth companies to the region. Meeting at the Harris Building Conference Center on State Street as a part of..."/>
Innovation Place initiative garners suppport [The Day, New London, Conn.]
PAREXEL International Corporation announced today it will be presenting at the Wells Fargo Healthcare Conference on Wednesday September 7, 2016 in Boston. Josef von Rickenbach, Chairman and Chief Executive Officer, will be making a presentation on PAREXEL and discussing business developments at 9:20a.m. ET. A live webcast of the presentation will be available through the“ Investors” section of PAREXEL’ s website at www.PAREXEL.com in the Upcoming Events portion of..."/>
PAREXEL International to Present at Wells Fargo Healthcare Conference
Regeneron Pharmaceuticals, Inc. will webcast a management presentation at the following investor conferences:. 2016 Credit Suisse Antibody Day at 10:00 a.m. Eastern Time on Wednesday, September 7, 2016 Morgan Stanley Global Healthcare Conference at 11:40 a.m. Eastern Time on Monday, September 12, 2016 Bank of America Merrill Lynch Global Healthcare Conference at 6:25 a.m. Eastern Time on Wednesday, September 14, 2016."/>
Regeneron Announces Upcoming 2016 Investor Conference Presentations
Knight Therapeutics Inc., a leading Canadian specialty pharmaceutical company, announced today that its strategic partner INTEGA Skin Sciences Inc., a Montreal-based dermatology company, has been acquired by Crescita Therapeutics Inc. for base consideration of $8.0 million payable in Crescita common shares valued at $2.44 a share. In January 2016, Knight entered into a secured loan agreement with INTEGA pursuant to which Knight loaned over..."/>
Knight Therapeutics Inc.: INTEGA Skin Primed for Crescita (Italian for Growth)
IIROC Trading Halt - CTX
AMAG Pharmaceuticals, Inc. today announced that company management will participate in an analyst-led fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 10:30 a.m. EDT.. A live audio webcast of the discussion will be accessible through the Investors section of the company’ s website at www.amagpharma.com and will be archived for 30 days. About AMAG AMAG is a biopharmaceutical company focused on..."/>
AMAG Pharmaceuticals to Present at Upcoming Investor Conference
PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®, today provided an update on its program for developing treatments for serious brain cancers that involve constituents of the Cannabis plant. These Cannabis- based cancer therapies, like PharmaCyte’ s pancreatic cancer therapy, will..."/>
PharmaCyte Biotech Reports on Progress in Its Medical Cannabis Program
Crescita Therapeutics Inc., a drug development company that owns topical products for use in the treatment of medical conditions related to dermatology and pain, today announced that it has acquired INTEGA Skin Sciences Inc., a Montreal-based dermatology company which develops, manufactures, sells and markets science-based quality skin care products."/>
Crescita Therapeutics™ Inc. Announces Acquisition of INTEGA Skin Sciences
Crescita Therapeutics Inc., a drug development company that owns topical products for use in the treatment of medical conditions related to dermatology and pain, today announced that it has acquired INTEGA Skin Sciences Inc., a Montreal-based dermatology company which develops, manufactures, sells and markets science-based quality skin care products."/>
Crescita Therapeutics™ Inc. Announces Acquisition of INTEGA Skin Sciences
Cerecor Inc., a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced it will be featured as a presenting company at the 23 rd Annual NewsMakers in the Biotech Industry Conference. The conference is being held on September 9, 2016, at the Millennium Broadway Hotel in New York City. Uli Hacksell, President and Chief Executive Officer of Cerecor, will..."/>
Cerecor to Present at 23rd Annual NewsMakers in the Biotech Industry Conference in New York City, September 9, 2016
Inovio Pharmaceuticals, Inc. today announced that the Company will present a corporate overview at the following upcoming conferences:. Citi 11th Annual Biotech Conference Mandarin Oriental, Boston, Thursday, September 8 th, 1 x1 meetings. 23 rd Annual Newsmakers in the Biotech Industry Millennium Broadway Hotel, New York, Friday, September 9 th, 11:00 am ET."/>
Inovio Pharmaceuticals to Present at Upcoming Investment Conferences
Apple has provoked a multitude of different reactions across the Atlantic. In Congress and on the presidential election trail there has been mild approval. No-one likes tax cheats and there is strong US political momentum aimed at repatriating the trillions of dollars of reserves that US companies have been accumulating in Bermuda and elsewhere to reinvest in the domestic economy."/>
Daily Mail, London, Alex Brummer column [Daily Mail, London]
Perrigo Company plc today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Epiduo ® Gel. Epiduo ® Gel is indicated for the treatment of acne vulgaris in patients 12 years of age and older."/>
Perrigo Announces Tentative FDA Approval For Generic Version Of Epiduo® Gel
St. Jude Medical AMPLATZER™ Amulet™ IDE trial, which will evaluate the safety and effectiveness of the company’ s AMPLATZER™ Amulet™ Left Atrial Appendage Occluder used to close the left atrial appendage..."/>
St. Jude Medical Launches Global Clinical Trial to Evaluate a New Therapy Option for Patients at an Increased Risk of Stroke Due to Atrial Fibrillation
Cerner client Sharp HealthCare, a leading health care provider in San Diego, has selected Cerner, a global leader in health care technology, to extend its electronic health record to Sharp Community Medical Group, one of two affiliated medical groups.. The PowerChart Ambulatory™ EHR will support more than 200 primary care and specialty physicians across Sharp’ s outpatient facilities and independent physician practices. Integration with the..."/>
Sharp HealthCare to Expand Cerner Digital Record
Evogene Ltd., a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries, today announced it will be featured as a presenting company at the 18 th Annual Rodman& Renshaw Global Investment Conference. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City.. Ofer Haviv, Evogene President and Chief Executive Officer, will provide an overview of the..."/>
Evogene Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
Aviragen Therapeutics, Inc., a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, September 8, 2016 at 4:30 p.m. ET to review the Company’ s financial results for the three month period and 2016 fiscal year ended June 30, 2016 and will provide an update on recent corporate developments. The Company will issue a press release summarizing its financial..."/>
Aviragen Therapeutics to Host Conference Call to Report Fourth Quarter and Fiscal Year 2016 Financial Results on September 8, 2016
RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that Mr. Adi Frish, RedHill’ s Senior VP Business Development& Licensing, will be presenting at the 9 th Annual BioPharm America International Partnering Conference, on Wednesday,..."/>
RedHill Biopharma to Present at the 9th Annual BioPharm America International Partnering Conference
Jaguar Animal Health, Inc., an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced additional topline results today from its study conducted in conjunction with researchers from Cornell University College of Veterinary Medicine to evaluate the efficacy of the prophylactic use of a second-generation, powder formulation of..."/>
Jaguar Animal Health Announces Additional Topline Results from Study of Second-Generation Formulation of Neonorm Calf Conducted in Association with Cornell University College of Veterinary Medicine
Amgen and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908, a bispecific T cell engager that targets B-cell maturation antigen, a potential target for multiple myeloma. BI 836908 is currently in Phase 1 studies. BI 836908 was originally licensed to Boehringer Ingelheim by Micromet before the company was acquired..."/>
Amgen Obtains Global Development And Commercial Rights From Boehringer Ingelheim For Investigational BiTE® Immuno-Oncology Drug For Multiple Myeloma
Halozyme Therapeutics, Inc., an oncology biotech developing novel oncology and drug-delivery therapies, today named biotech veteran Mark J. Gergen as senior vice president and chief operating officer, reporting to Dr. Helen Torley, president and chief executive officer. Gergen will be responsible for corporate development, including the management of Halozyme's proprietary ENHANZE™ platform collaborations and overseeing the global..."/>
Halozyme Names Mark J. Gergen As Chief Operating Officer
CANTEL MEDICAL CORP. is pleased to announce that Seth M. Yellin has recently been promoted to Executive Vice President, Strategy and Corporate Development from Senior Vice President, Corporate Development. In his new role, Mr. Yellin will have responsibility for Cantel's strategic planning function along with his current role of corporate development, which includes leading the Company's active acquisition program."/>
Cantel Medical Promotes Seth M. Yellin to Executive Vice President
AstraZeneca has been forced to fork out pounds sterling 4.2 m to settle a bribery probe over allegations staff used gifts and cash to persuade doctors to buy its drugs. The Anglo-Swedish pharmaceutical giant is accused of setting up bogus conferences, organising false travel documents and creating fake tax receipts to' reward or influence' healthcare providers. The US markets watchdog claims staff at the firm made' numerous improper payments' to doctors in China and..."/>
It set up bogus conferences, supplied fake travel invoices and handed gifts to hospitals [Daily Mail, London]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology676 Articles
Consumer Discretionary627 Articles
Financials448 Articles
Industrials382 Articles
Health Care382 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.